A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
ADCs
Cancer
NSCLC
Review
Targeted therapy
Journal
Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
13
01
2022
revised:
02
04
2022
accepted:
10
04
2022
pubmed:
27
4
2022
medline:
4
5
2022
entrez:
26
4
2022
Statut:
ppublish
Résumé
Even though both targeted and immunotherapy-based therapies have been established as frontline standard-of-care for patients with advanced lung cancer, adverse events, resistance, and disease progression remain unavoidable in most instances. In this scenario, chemotherapy is a popular salvage option, but it has restricted therapeutic index. Antibody-drug conjugates (ADCs) have emerged as a viable option. ADCs combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy to deliver cytotoxic payloads to cancer cells in a direct fashion. Among the promising ADCs used in advanced solid tumors, HER2 targeted ADCs of trastuzumab ematansine and trastuzumab deruxtecan are key drugs in this field.
Identifiants
pubmed: 35472631
pii: S0305-7372(22)00057-3
doi: 10.1016/j.ctrv.2022.102393
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents
0
Immunoconjugates
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102393Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.